← ANALYST RATINGS · TIPRANKS
Revolution Medicines (RVMD): analyst forecast and price target
Analyst consensus
Strong Buy18 Buy0 Hold0 Sell
Ratings of 18 analysts in the last 3 months · top analysts only12-month forecast
Based on 18 price targets given in the last 3 months, the average target is $259, the highest $320, the lowest $210. The average is +45.4% from the last price of $178.
Analyst ratings 27
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $275 | Buy | +54.5% | Reiterated | 15.10.26on TipRanks Oct 16 07:30 | −2.5%next day −4.9% | ↗ |
| Sharon Zackfia★★★★★★★★★★#4054 · hits 44% · avg +3.0% | William Blair | $226 | Buy | +27.0% | Initiated | 15.10.26on TipRanks Oct 16 05:55 | −2.5%next day −4.9% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $275 | Buy | +54.5% | Reiterated | 15.10.26on TipRanks 07:30 | −2.5%next day −4.9% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $259 → $260+0.4% | Buy | +46.1% | Reiterated | 14.10.26on TipRanks 06:50 | +3.8%next day −2.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $203 → $213+4.9% | Buy | +19.7% | Upgrade | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $185 → $201+8.6% | Hold | +12.9% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $205 → $200−2.4% | Hold | +12.4% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $212 → $208−1.9% | Hold | +16.9% | Downgrade | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $198 → $191−3.5% | Hold | +7.3% | Reiterated | 14.10.26on TipRanks Oct 13 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $224 → $200−10.7% | Hold | +12.4% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $265 → $264−0.4% | Buy | +48.3% | Reiterated | 09.10.26on TipRanks 08:25 | +0.3%next day +2.3% · 5 days −4.3% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 08.10.26on TipRanks 15:45 | −5.9%next day +0.3% · 5 days +0.9% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | — | Buy | — | Reiterated | 08.10.26on TipRanks 12:06 | −5.9%next day +0.3% · 5 days +0.9% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $239 → $240+0.4% | Buy | +34.9% | Reiterated | 07.10.26on TipRanks 09:05 | +0.7%next day −5.9% · 5 days −2.7% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $315 | Buy | +77.0% | Reiterated | 05.10.26on TipRanks 10:55 | −0.2%next day −4.3% · 5 days −7.0% | ↗ |
| Leah R. Cann★★★★★★★★★★#11464 · hits 38% · avg −2.6% | Brookline Capital Markets | $318 | Buy | +78.7% | Initiated | 28.09.26on TipRanks 07:25 | −0.8%next day +1.5% · 5 days +1.7% | ↗ |
| Jeffrey Walch★★★★★★★★★★#5662 · hits 100% · avg +19.5% | Bernstein | $179 | Hold | +0.6% | Reiterated | 25.09.26on TipRanks Sep 26 10:20 | +2.0%next day −0.8% · 5 days +1.0% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $267 | Buy | +50.0% | Initiated | 24.09.26on TipRanks 04:30 | +4.9%next day +2.0% · 5 days +3.4% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $255 | Buy | +43.3% | Initiated | 10.09.26on TipRanks 05:50 | −1.5%next day −0.6% · 5 days −3.8% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $270 | Buy | +51.7% | Reiterated | 03.09.26on TipRanks 10:05 | −0.3%next day 0.0% · 5 days −2.2% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $246 | Buy | +38.2% | Reiterated | 01.09.26on TipRanks Sep 2 08:05 | +2.8%next day −0.7% · 5 days −1.1% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $220 → $265+20.5% | Buy | +48.9% | Reiterated | 28.08.26on TipRanks 07:13 | −5.8%next day −0.8% · 5 days +0.9% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $201 → $225+11.9% | Buy | +26.4% | Reiterated | 27.08.26on TipRanks Sep 1 09:25 | +2.0%next day −5.8% · 5 days −4.9% | ↗ |
| Sean McCutcheon★★★★★★★★★★#1382 · hits 43% · avg +39.7% | Raymond James | $230 → $248+7.8% | Buy | +39.4% | Reiterated | 27.08.26on TipRanks 08:35 | +2.0%next day −5.8% · 5 days −4.9% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $230 → $260+13.0% | Buy | +46.1% | Reiterated | 27.08.26on TipRanks 08:20 | +2.0%next day −5.8% · 5 days −4.9% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $230 → $320+39.1% | Buy | +79.8% | Reiterated | 27.08.26on TipRanks 08:00 | +2.0%next day −5.8% · 5 days −4.9% | ↗ |
| Eva Fortea Verdejo★★★★★★★★★★#231 · hits 80% · avg +54.1% | Wells Fargo | $240 | Buy | +34.9% | Assigned | 27.08.26on TipRanks 07:15 | +2.0%next day −5.8% · 5 days −4.9% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $195 → $280+43.6% | Buy | +57.3% | Reiterated | 27.08.26on TipRanks 06:15 | +2.0%next day −5.8% · 5 days −4.9% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $165 → $220+33.3% | Buy | +23.6% | Reiterated | 10.08.26on TipRanks 08:20 | +0.9%next day −0.4% · 5 days +2.5% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 10.08.26on TipRanks 07:50 | +0.9%next day −0.4% · 5 days +2.5% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $172 → $210+22.1% | Buy | +18.0% | Reiterated | 06.08.26on TipRanks 07:45 | +0.4%next day +3.1% · 5 days +0.9% | ↗ |
| Jonathan Chang★★★★★★★★★★#2398 · hits 37% · avg +7.3% | Leerink Partners | $115 → $147+27.8% | Buy | −17.4% | Reiterated | 13.04.26on TipRanks 10:20 | +40.4%next day +6.6% · 5 days +4.0% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | $72.00 | Buy | −59.5% | Reiterated | 23.10.25on TipRanks 04:50 | +0.3%next day +1.1% · 5 days +9.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Revolution Medicines
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 05.10.26: target $258 at a price of $207 (+24.8%); now: $257 at $178 (+44.5%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 6 | 3 | 4 | 5 |
| Buy | 41 | 56 | 43 | 65 | 52 | 48 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-2.35 (from $-2.65 to $-2.07). Last quarter: $-3.06.
Best top-analyst consensus in the sector · Healthcare
About Revolution Medicines
- CEO: Mark A. Goldsmith
- Employees: 883
- 700 Saginaw Drive, Redwood City, CA, 94063, US
- www.revmed.com
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Data from the stock’s TipRanks forecast page, read 10 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗